<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02755662</url>
  </required_header>
  <id_info>
    <org_study_id>RESMED Estamps 001</org_study_id>
    <nct_id>NCT02755662</nct_id>
  </id_info>
  <brief_title>Clinical Impact of 2 Types of Mandibular Retention Devices - Narval O.R.M CadCam Design vs Narval O.R.M Traditional Design - on Obstructive Sleep Apnea (OSA) Therapy: ESTAMPS Study</brief_title>
  <acronym>ESTAMPS</acronym>
  <official_title>Clinical Impact of 2 Types of Mandibular Retention Devices - Narval O.R.M Cad Cam Design vs Narval O.R.M Traditional Design - on Obstructive Sleep Apnea Syndrome (OSA) Therapy: ESTAMPS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ESTAMPS is a randomized clinical trial with a crossover design:

      Main objective is to compare impact of 2 different Mandibular Retention Device (MRD) designs
      (Narval MRD CadCam (CC) design vs Narval MRD traditional (trad) design) on upper airway
      volume

      secondary objectives: To evaluate the maximal mandibular propulsion according to the type of
      MRD To evaluate benefits on quality of life, sleepiness and OSA symptoms To evaluate impact
      of MRD design on therapy efficacy and tolerance To evaluate impact of MRD design on
      mandibular positioning
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis ORCADES results suggest that Narval O.R.M CC could be more efficient than Narval
      MRD trad to reduce AHI whatever the initial OSA severity 79% of CC MRD patients have at least
      an AHI reduction of 50% (vs. 61% with a trad Narval MRD, p=0.0031) 66% of CC MRD patients get
      a complete answer with an AHI reduction &lt;10 (vs. 49% with a trad Narval MRD, p=0.0017) The
      investigators think that differences seen in the ORCADES study between the 2 MRD is due to a
      different impact on upper airway volume
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>upper airway volume</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will measure upper airway volume (cm3) changes produced by 2 different Mandibular Retention Devices in Obstructive sleep apnea syndrome (OSA) patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximal mandibular propulsion</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will measure the maximal mandibular propulsion (in millimeter) at the end of MRD titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of sleep</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will use specific quality of sleep questionnaire: Pittsburgh sleep quality index (PSQI),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleepiness</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will use a specific sleepiness questionnaire: Epworth sleepiness scale (ESS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD therapy efficacy</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will measure the residual Apnea and Hypopnea Index (AHI) via polygraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mandibular positioning</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will measure the mandibular positioning under MRD therapy (in millimeter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occlusal vertical dimension</measure>
    <time_frame>1 month</time_frame>
    <description>investigators will measure the occlusal vertical dimension changes (in millimeter) between the 2 type of MRD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>Narval O.R.M CC™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First mandibular retention device : Narval O.R.M CC™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narval O.R.M™ trad</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second mandibular retention device : Narval O.R.M TRAD™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mandibular Retention Device</intervention_name>
    <arm_group_label>Narval O.R.M CC™</arm_group_label>
    <arm_group_label>Narval O.R.M™ trad</arm_group_label>
    <other_name>Narval O.R.M CC™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a mild OSA syndrome (5&lt;AHI&lt;30) and mild to moderate sleepiness without
             cardiac comorbidities or patients with mild to severe OSA syndrome (IAH&gt;15) who do not
             tolerate or refuse CPAP therapy

          -  Patients ≥ 18 years old

          -  Patient is able to fully understand study information and provide written informed
             consent

        Exclusion Criteria:

          -  MRD contraindication

          -  Clinical trial classic exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Baptiste Kerbrat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rouen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2016</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea Syndrome</keyword>
  <keyword>mandibular repositioning device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

